NR1H4 and metabolic dysfunction-associated steatotic liver disease: In addition, OCA and several other pharmacological FXR ligands are being evaluated in clinical trials for their therapeutic value in other chronic liver diseases, including primary sclerosing cholangitis (PSC) and non-alcoholic fatty liver disease (NAFLD).